Molecule intelOpportunity: ModerateEssential

Sertraline

75 brands · 52 companies · product forms

ATC: N06AB06

Opportunity snapshot

Launch attractiveness
38
Market saturation
85
Price room
100
Regulatory risk
0
75
brands
52
companies
Rs 570
median price
59
price points
52.11x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 4%

Price room

Across observed sources and strengths
CheapestRs 61.8
MedianRs 570
Most expensiveRs 3,220.2
Spread52.11×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 52.11x across 59 trusted points (Rs 61.8-3220.2). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Sertraline — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(15) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

52 canonical companies and 75 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 52.11x across 59 trusted points (Rs 61.8-3220.2). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.